The high‐risk group (patients with ≥2 cm polyps or polyps treated by ESD) displayed greater prevalence of cerebrovascular disease, arterial thrombosis, chronic heart disease, ischemic heart disease, gastrointestinal ulcer, malignant tumor with no metastasis, hypertension, diabetes, PPI use, and COX‐2 inhibitor use than did the low‐risk group (patients with <2 cm polyps). The gene discussed is PTGS2; the disease is cancer.